肺上皮样血管内皮瘤并发慢性阻塞性肺疾病1例报告及文献复习

doi:10.13481/j.1671-587x.20210127

摘要/Abstract

摘要： 目的

分析肺上皮样血管内皮瘤（PEHE）并发慢性阻塞性肺疾病（COPD）患者的临床表现、诊断及治疗经过，提高临床医生对PEHE的认识。

方法

收集1例并发COPD的PEHE患者临床资料，并结合相关文献，总结其临床诊断和治疗方法。

结果

患者，男性，74岁，因反复胸闷、气喘半年，加重半月入院。查体，桶状胸，叩诊两肺过清音，呼吸音减低，无其他明显阳性体征。肺功能，第１秒用力呼气容积（FEV1）占预计值58%，FEV1/用力肺活量（FVC）56.9%。胸部CT检查结果提示两肺多发大小不等结节，两肺慢性支气管炎及肺气肿改变伴肺大泡形成。支气管镜活检见异型细胞巢，结合临床和免疫标记符合PEHE诊断。给予恩度和支气管扩张剂治疗后好转并出院。后续患者胸闷、气喘症状再发，以COPD急性加重入院对症治疗，继续采用恩度抗肿瘤治疗，患者症状改善不明显，并伴有乏力和全身多处骨关节疼痛。影像学评估提示患者出现肝内转移灶和多发骨转移，改用安罗替尼口服抗肿瘤及对症治疗。此后患者病情继续进展，出现呼吸衰竭、低蛋白血症和继发感染，影像学评估两肺病灶进展，对症及支持治疗无效，最终患者死亡。

结论

PEHE患者临床症状不典型，并发COPD时更易被忽视，COPD的存在也同样会影响治疗方案的选择。

关键词: 上皮样血管内皮瘤, 肺肿瘤, 慢性阻塞性肺疾病

Abstract: Objective

To analyze the clinical manifestation， diagnosis and treatment of the patient with pulmonary epithelioid hemangioendothelioma （PEHE） combined with chronic obstructive pulmonary disease（COPD）， and to develop the clinicians’ understanding of PEHE.

Methods

The clinical data of a patient with PEHE complicated with COPD were collected； the relevant literatures were reviewed， and its diagnosis and treatment methods were summarized.

Results

The male patient was 74 years old， who was hospitalized because of repeated chest tightness and asthma for half a year and half a month of deterioration. Physical examination showed barrel chest， and hyperresonant sounds were heard when percussing lungs； the respiratory sounds of lungs were reduced； there were no other obvious positive signs. The examination results of pulmonary function showed that forced expiratory volume in 1 second （FEV1） accounted for 58% of predicted value and FEV1/ forced vital capacity （FVC） was 56.9%. The chest CT results showed multiple nodules with different sizes， chronic bronchitis and bullous emphysema in both lungs. The bronchoscope results showed abnormal cell-nest， the clinical and immunologic markers were considered， and the results met the diagnosis of PEHE. The patient got better after treated with endostar and bronchodilator and was discharged from hospital. After that， chest tightness and asthma occurred again， so the patient was admitted to the hospital for symptomatic treatment because of COPD， but the symptoms were not relieved significantly and fatigue and systemic pain were found after endostar was given. The evaluation of imaging revealed intrahepatic metastases，and bone metastases in several areas， so the patient received anti-tumor and symptomatic treatment by taking anlotinib. Then， respiratory failure， hypoalbuminemia and secondary infection occurred. So symptomatic treatment was given after assessing the lesions of both lungs by imaging. But the patient was dead.

Conclusion

The clinical symptoms of PEHE are atypical， and it is easy to be ignored when a patient is accompanied by COPD. The presence of COPD can also affect what kind of treatment plan can be used.

Key words: epithelioid hemangioendothelioma, pulmonary neoplasms, chronic obstructive pulmonary disease

中图分类号:

R734.2

黄静,丁明,朱晓莉,陈平圣,韩淑华. 肺上皮样血管内皮瘤并发慢性阻塞性肺疾病1例报告及文献复习[J]. 吉林大学学报(医学版), 2021, 47(1): 196-202.

Jing HUANG,Ming DING,Xiaoli ZHU,Pingsheng CHEN,Shuhua HAN. Pulmonary epithelioid hemangioendothelioma complicated with chronic obstructive pulmonary disease:A case report and literature review[J]. Journal of Jilin University(Medicine Edition), 2021, 47(1): 196-202.

图/表 4

参考文献 26

1	DAIL D， LIEBOW A. Intravascular bronchioloalveolar tumor［J］. Am J Pathol， 1975， 78（1）： 6-7.
2	LAU K， MASSAD M， POLLAK C， et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement： insights from an internet registry in the study of a rare cancer ［J］. Chest， 2011， 140（5）： 1312-1318.
3	ROSENBERG A， AGULNIK M. Epithelioid hemangioendothelioma：update on diagnosis and treatment ［J］. Curr Treat Options Oncol， 2018， 19（4）： 19.
4	BAGAN P， HASSAN M， LE PIMPEC BARTHES F， et al. Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma： A review of the literature ［J］. Ann Thorac Surg， 2006， 82（6）： 2010-2013.
5	LAMAR J M， MOTILAL NEHRU V， WEINBERG G. Epithelioid hemangioendothelioma as a model of YAP/TAZ-driven cancer： Insights from a rare fusion sarcoma ［J］. Cancers （Basel）， 2018， 10（7）：E229.
6	KIM E Y， KIM T S， HAN J， et al. Thoracic epithelioid hemangioendothelioma： imaging and pathologic features ［J］. Acta Radiol， 2011， 52（2）： 161-166.
7	HAN Y J， KIM H J， KONG K A， et al. Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy：a systematic review and meta-analysis ［J］. PLoS One， 2018， 13（1）： e0191590.
8	FLUCKE U， VOGELS R J， DE SAINT AUBAIN SOMERHAUSEN N， et al. Epithelioid Hemangioendothelioma： clinicopathologic， immunhisto-chemical， and molecular genetic analysis of 39 cases ［J］. Diagn Pathol， 2014， 9：131.
9	ANDERSON T， ZHANG L， HAMEED M， et al. Thoracic epithelioid malignant vascular tumors： a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions ［J］. Am J Surg Pathol， 2015， 39（1）： 132-139.
10	SHON W， BILLINGS S D. Epithelioid vascular tumors： A review ［J］. Adv Anat Pathol， 2019， 26（3）： 186-197.
11	GILL R， O’DONNELL R J， HORVAI A. Utility of immunohistochemistry for endothelial markers in distinguishing epithelioid hemangioendothelioma from carcinoma metastatic to bone ［J］. Arch Pathol Lab Med， 2009， 133（6）： 967-972.
12	PAPKE D J JR，HORNICK J L. What is new in endothelial neoplasia？［J］. Virchows Arch， 2020， 476（1）： 17-28.
13	ERRANI C， ZHANG L， SUNG Y S， et al. A novel WWTR1-CAMTA1 genes fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites ［J］. Genes Chromosome Cancer， 2011， 50（8）： 644-653.
14	MEHRABI A， KASHFI A， FONOUNI H， et al. Primary malignant hepatic epithelioid hemangioendothelioma： a comprehensive review of the literature with emphasis on the surgical therapy ［J］. Cancer， 2006， 107（9）： 2108-2121.
15	KITAICHI M， NAGAI S， NISHIMURA K， et al. Pulmonary epithelioid haemangioendothelioma in 21 patients， including three with partial spontaneous regression ［J］. Eur Respir J， 1998， 12（1）： 89-96.
16	KANEMURA S， KURIBAYASHI K， MORIYA Y， et al. Pemetrexed for epithelioid haemangioendothelioma of the pleura ［J］. Respirol Case Rep， 2016， 4（6）： e00191.
17	WOO J H， KIM T J， LEE K S， et al. Epithelioid hemangioendothelioma in the thorax： Clinicopathologic， CT， PET， and prognostic features ［J］. Medicine （Madr）， 2016， 95（30）： e4348.
18	YE B， LI W， FENG J， et al. Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy： Report of three cases and review of the literature ［J］. Oncol Lett， 2013， 5（5）： 1491-1496.
19	PINET C， MAGNAN A， GARBE L， et al. Aggressive form of pleural epithelioid haemangioendothelioma： complete response after chemotherapy ［J］. Eur Respir J， 1999， 14（1）： 237-238.
20	MERIKAS E， GRAPSA D， DIKOUDI E， et al. Epithelioid hemangioendothelioma treated with bevacizumab： A case series ［J］. Cancer Treat Commun， 2015， 4（1）：59-64.
21	ZHENG Z P， WANG H Y， JIANG H L， et al. Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma： A case report and literature review ［J］. Medicine （Baltimore）， 2017， 96（45）： e8507.
22	SEMENISTY V， NARODITSKY I， KEIDAR Z， et al. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option： case report and review of anti-angiogenic treatment options ［J］. BMC Cancer， 2015， 15：402.
23	HANSEN C G， NG Y L， LAM W L， et al. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1 ［J］. Cell Res， 2015， 25（12）： 1299-1313.
24	STACCHIOTTI S， PROVENZANO S， DAGRADA G， et al. Sirolimus in Advanced epithelioid hemangioendothelioma： A retrospective case-series analysis from the Italian rare cancer network database ［J］. Ann Surg Oncol， 2016， 23（9）： 2735-2744.
25	DEYRUP A T， TIGHIOUART M， MONTAG A G， et al. Epithelioid hemangioendothelioma of soft tissue： a proposal for risk stratification based on 49 cases ［J］. Am J Surg Pathol， 2008， 32（6）： 924-927.
26	AMIN R M， HIROSHIMA K， KOKUBO T， et al. Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report ［J］. Respirology， 2006， 11（6）： 818-825.

[1]	侯从岭,芦晓帆,雷小婷,李彬,赵润杨. 异钩藤碱上调miR-192-5p对TNF-α诱导的人支气管上皮细胞凋亡和炎症因子释放的作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 595-607.
[2]	穆春青,周磊,赵楠,王红,李智. 二甲双胍通过PI3K/AKT/GSK3β信号通路对肺癌A549细胞增殖的影响[J]. 吉林大学学报(医学版), 2021, 47(3): 637-643.
[3]	陈琪,李勇,徐金瑞,杨易. Wnt5a在肺相关疾病发生发展过程中作用的研究进展Research progress in roles of Wnt5a in occurrence and development of lung-related diseases[J]. 吉林大学学报(医学版), 2021, 47(1): 237-242.
[4]	苗双,倪娜,杨丽娟,武艳,李雪琳,董洪亮,宫凯凯. aaptamine 与顺铂联合用药对人肺腺癌顺铂耐药A549/DDP细胞的协同抑制作用[J]. 吉林大学学报(医学版), 2021, 47(1): 8-15.
[5]	周宁, 武睿, 马振凯, 陈微微, 李雪琳, 宫凯凯, 杨丽娟, 代娟娟, 武艳. 下调ADAR1表达对人肺癌细胞增殖、迁移和上皮间质转化的影响[J]. 吉林大学学报(医学版), 2020, 46(04): 669-674.
[6]	贾答淇, 孔雯聪, 苏荣健, 杜晓媛, 贺武斌. 巨噬细胞刺激1受体抑制剂BMS777607对肺癌细胞增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2020, 46(04): 739-744.
[7]	张爽爽, 贺武斌, 苏荣健, 杜晓媛. EZH2抑制剂GSK126对肺腺癌细胞增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2020, 46(04): 786-791.
[8]	周宁, 郭纪伟, 代娟娟, 李雪琳, 席思川, 宫凯凯, 武艳. YAP对非小细胞肺癌细胞增殖和迁移能力的影响[J]. 吉林大学学报(医学版), 2019, 45(06): 1320-1326.
[9]	梁小波, 吴德洪, 王星, 张沄, 王孝芸, 李国平. 鼻内滴注烟草提取物和脂多糖建立慢性阻塞性肺疾病小鼠模型的评价[J]. 吉林大学学报(医学版), 2019, 45(06): 1454-1458.
[10]	任芳萍, 蒋延文. 雾化吸入N-乙酰半胱氨酸在老年慢性阻塞性肺疾病急性加重患者治疗中的应用[J]. 吉林大学学报(医学版), 2019, 45(05): 1141-1145.
[11]	王上宁, 王思思, 田肃岩, 李佳林, 刘伟. 肺腺癌患者单孔胸腔镜肺叶切除术后早期外周血淋巴细胞亚群变化及其临床意义[J]. 吉林大学学报(医学版), 2019, 45(03): 606-613.
[12]	侯海龙, 唐颖, 曲兴龙, 华树成. 右美托咪定联合无创通气治疗AECOPD并发肺性脑病患者的临床疗效及安全性评价[J]. 吉林大学学报(医学版), 2018, 44(05): 1014-1019.
[13]	张雪阳, 马骥, 孟广平, 王琦, 李伟, 徐艳玲, 张捷, 高鹏. 基于吉林省长春市区居民肺功能筛查的慢性阻塞性肺疾病患病现况调查分析[J]. 吉林大学学报(医学版), 2017, 43(05): 1047-1052.
[14]	刘相良, 纪伟, 李理, 赵颖华, 贾琳, 万志强, 陈晓, 李薇. 盐酸厄洛替尼片及耐药后化疗联合贝伐珠单抗注射液治疗肺腺癌1例报告并文献复习[J]. 吉林大学学报(医学版), 2017, 43(05): 1019-1024.
[15]	张晶, 王志成, 赵大力, 卢晓倩, 沈智渊, 齐亚莉. 电离辐射对肺癌H460细胞凋亡的影响及其机制[J]. 吉林大学学报(医学版), 2017, 43(03): 522-526.